Current therapeutic regimens for patients who have symptoms of DKD include angiotensin-converting enzyme inhibitors, angiotensin II receptor type 1 blockers (ARBs), and statins that can retard, but not prevent, the progression of incidence of end-stage kidney disease in diabetes. This evidence concerns the gene AGTR1 and diabetic kidney disease.